Global RNAi for Therapeutic Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 258028
  • calendar_today Published On: Jan, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The RNAi for Therapeutic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global RNAi for Therapeutic market size is estimated to be worth US$ 181.1 million in 2021 and is forecast to a readjusted size of USD 2031.2 million by 2028 with a CAGR of 41.2% during review period. Cancer accounting for % of the RNAi for Therapeutic global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While siRNA segment is altered to a % CAGR between 2022 and 2028.

Global key companies of RNAi for Therapeutic include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, and Mirna Therapeutics, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

RNAi for Therapeutic market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

siRNA

miRNA

shRNA

Market segment by Application, can be divided into

Cancer

Cardiovascular

HBV

Others

Market segment by players, this report covers

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead

Dicerna Pharmaceuticals

Mirna Therapeutics

Quark Pharmaceuticals

RXi Pharmaceuticals

Silence Therapeutics

Benitec Biopharma

miRagen Therapeutics

Sylentis

Gradalis

Sirnaomics

Silenseed

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe RNAi for Therapeutic product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of RNAi for Therapeutic, with revenue, gross margin and global market share of RNAi for Therapeutic from 2019 to 2022.

Chapter 3, the RNAi for Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and RNAi for Therapeutic market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe RNAi for Therapeutic research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of RNAi for Therapeutic

1.2 Classification of RNAi for Therapeutic by Type

1.2.1 Overview: Global RNAi for Therapeutic Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global RNAi for Therapeutic Revenue Market Share by Type in 2021

1.2.3 siRNA

1.2.4 miRNA

1.2.5 shRNA

1.3 Global RNAi for Therapeutic Market by Application

1.3.1 Overview: Global RNAi for Therapeutic Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Cancer

1.3.3 Cardiovascular

1.3.4 HBV

1.3.5 Others

1.4 Global RNAi for Therapeutic Market Size & Forecast

1.5 Global RNAi for Therapeutic Market Size and Forecast by Region

1.5.1 Global RNAi for Therapeutic Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global RNAi for Therapeutic Market Size by Region, (2017-2022)

1.5.3 North America RNAi for Therapeutic Market Size and Prospect (2017-2028)

1.5.4 Europe RNAi for Therapeutic Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific RNAi for Therapeutic Market Size and Prospect (2017-2028)

1.5.6 South America RNAi for Therapeutic Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa RNAi for Therapeutic Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 RNAi for Therapeutic Market Drivers

1.6.2 RNAi for Therapeutic Market Restraints

1.6.3 RNAi for Therapeutic Trends Analysis

2 Company Profiles

2.1 Alnylam Pharmaceuticals

2.1.1 Alnylam Pharmaceuticals Details

2.1.2 Alnylam Pharmaceuticals Major Business

2.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions

2.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Alnylam Pharmaceuticals Recent Developments and Future Plans

2.2 Arbutus Biopharma (Tekmira)

2.2.1 Arbutus Biopharma (Tekmira) Details

2.2.2 Arbutus Biopharma (Tekmira) Major Business

2.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions

2.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Arbutus Biopharma (Tekmira) Recent Developments and Future Plans

2.3 Arrowhead

2.3.1 Arrowhead Details

2.3.2 Arrowhead Major Business

2.3.3 Arrowhead RNAi for Therapeutic Product and Solutions

2.3.4 Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Arrowhead Recent Developments and Future Plans

2.4 Dicerna Pharmaceuticals

2.4.1 Dicerna Pharmaceuticals Details

2.4.2 Dicerna Pharmaceuticals Major Business

2.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions

2.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Dicerna Pharmaceuticals Recent Developments and Future Plans

2.5 Mirna Therapeutics

2.5.1 Mirna Therapeutics Details

2.5.2 Mirna Therapeutics Major Business

2.5.3 Mirna Therapeutics RNAi for Therapeutic Product and Solutions

2.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Mirna Therapeutics Recent Developments and Future Plans

2.6 Quark Pharmaceuticals

2.6.1 Quark Pharmaceuticals Details

2.6.2 Quark Pharmaceuticals Major Business

2.6.3 Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions

2.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Quark Pharmaceuticals Recent Developments and Future Plans

2.7 RXi Pharmaceuticals

2.7.1 RXi Pharmaceuticals Details

2.7.2 RXi Pharmaceuticals Major Business

2.7.3 RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions

2.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 RXi Pharmaceuticals Recent Developments and Future Plans

2.8 Silence Therapeutics

2.8.1 Silence Therapeutics Details

2.8.2 Silence Therapeutics Major Business

2.8.3 Silence Therapeutics RNAi for Therapeutic Product and Solutions

2.8.4 Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Silence Therapeutics Recent Developments and Future Plans

2.9 Benitec Biopharma

2.9.1 Benitec Biopharma Details

2.9.2 Benitec Biopharma Major Business

2.9.3 Benitec Biopharma RNAi for Therapeutic Product and Solutions

2.9.4 Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Benitec Biopharma Recent Developments and Future Plans

2.10 miRagen Therapeutics

2.10.1 miRagen Therapeutics Details

2.10.2 miRagen Therapeutics Major Business

2.10.3 miRagen Therapeutics RNAi for Therapeutic Product and Solutions

2.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 miRagen Therapeutics Recent Developments and Future Plans

2.11 Sylentis

2.11.1 Sylentis Details

2.11.2 Sylentis Major Business

2.11.3 Sylentis RNAi for Therapeutic Product and Solutions

2.11.4 Sylentis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Sylentis Recent Developments and Future Plans

2.12 Gradalis

2.12.1 Gradalis Details

2.12.2 Gradalis Major Business

2.12.3 Gradalis RNAi for Therapeutic Product and Solutions

2.12.4 Gradalis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Gradalis Recent Developments and Future Plans

2.13 Sirnaomics

2.13.1 Sirnaomics Details

2.13.2 Sirnaomics Major Business

2.13.3 Sirnaomics RNAi for Therapeutic Product and Solutions

2.13.4 Sirnaomics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Sirnaomics Recent Developments and Future Plans

2.14 Silenseed

2.14.1 Silenseed Details

2.14.2 Silenseed Major Business

2.14.3 Silenseed RNAi for Therapeutic Product and Solutions

2.14.4 Silenseed RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Silenseed Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global RNAi for Therapeutic Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 RNAi for Therapeutic Players Market Share in 2021

3.2.2 Top 10 RNAi for Therapeutic Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 RNAi for Therapeutic Players Head Office, Products and Services Provided

3.4 RNAi for Therapeutic Mergers & Acquisitions

3.5 RNAi for Therapeutic New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global RNAi for Therapeutic Revenue and Market Share by Type (2017-2022)

4.2 Global RNAi for Therapeutic Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global RNAi for Therapeutic Revenue Market Share by Application (2017-2022)

5.2 Global RNAi for Therapeutic Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America RNAi for Therapeutic Revenue by Type (2017-2028)

6.2 North America RNAi for Therapeutic Revenue by Application (2017-2028)

6.3 North America RNAi for Therapeutic Market Size by Country

6.3.1 North America RNAi for Therapeutic Revenue by Country (2017-2028)

6.3.2 United States RNAi for Therapeutic Market Size and Forecast (2017-2028)

6.3.3 Canada RNAi for Therapeutic Market Size and Forecast (2017-2028)

6.3.4 Mexico RNAi for Therapeutic Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe RNAi for Therapeutic Revenue by Type (2017-2028)

7.2 Europe RNAi for Therapeutic Revenue by Application (2017-2028)

7.3 Europe RNAi for Therapeutic Market Size by Country

7.3.1 Europe RNAi for Therapeutic Revenue by Country (2017-2028)

7.3.2 Germany RNAi for Therapeutic Market Size and Forecast (2017-2028)

7.3.3 France RNAi for Therapeutic Market Size and Forecast (2017-2028)

7.3.4 United Kingdom RNAi for Therapeutic Market Size and Forecast (2017-2028)

7.3.5 Russia RNAi for Therapeutic Market Size and Forecast (2017-2028)

7.3.6 Italy RNAi for Therapeutic Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific RNAi for Therapeutic Revenue by Type (2017-2028)

8.2 Asia-Pacific RNAi for Therapeutic Revenue by Application (2017-2028)

8.3 Asia-Pacific RNAi for Therapeutic Market Size by Region

8.3.1 Asia-Pacific RNAi for Therapeutic Revenue by Region (2017-2028)

8.3.2 China RNAi for Therapeutic Market Size and Forecast (2017-2028)

8.3.3 Japan RNAi for Therapeutic Market Size and Forecast (2017-2028)

8.3.4 South Korea RNAi for Therapeutic Market Size and Forecast (2017-2028)

8.3.5 India RNAi for Therapeutic Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia RNAi for Therapeutic Market Size and Forecast (2017-2028)

8.3.7 Australia RNAi for Therapeutic Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America RNAi for Therapeutic Revenue by Type (2017-2028)

9.2 South America RNAi for Therapeutic Revenue by Application (2017-2028)

9.3 South America RNAi for Therapeutic Market Size by Country

9.3.1 South America RNAi for Therapeutic Revenue by Country (2017-2028)

9.3.2 Brazil RNAi for Therapeutic Market Size and Forecast (2017-2028)

9.3.3 Argentina RNAi for Therapeutic Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa RNAi for Therapeutic Revenue by Type (2017-2028)

10.2 Middle East & Africa RNAi for Therapeutic Revenue by Application (2017-2028)

10.3 Middle East & Africa RNAi for Therapeutic Market Size by Country

10.3.1 Middle East & Africa RNAi for Therapeutic Revenue by Country (2017-2028)

10.3.2 Turkey RNAi for Therapeutic Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia RNAi for Therapeutic Market Size and Forecast (2017-2028)

10.3.4 UAE RNAi for Therapeutic Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global RNAi for Therapeutic Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global RNAi for Therapeutic Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market RNAi for Therapeutic Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global RNAi for Therapeutic Revenue (USD Million) by Region (2017-2022)

Table 5. Global RNAi for Therapeutic Revenue Market Share by Region (2023-2028)

Table 6. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 7. Alnylam Pharmaceuticals Major Business

Table 8. Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions

Table 9. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Arbutus Biopharma (Tekmira) Corporate Information, Head Office, and Major Competitors

Table 11. Arbutus Biopharma (Tekmira) Major Business

Table 12. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions

Table 13. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Arrowhead Corporate Information, Head Office, and Major Competitors

Table 15. Arrowhead Major Business

Table 16. Arrowhead RNAi for Therapeutic Product and Solutions

Table 17. Arrowhead RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Dicerna Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 19. Dicerna Pharmaceuticals Major Business

Table 20. Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions

Table 21. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Mirna Therapeutics Corporate Information, Head Office, and Major Competitors

Table 23. Mirna Therapeutics Major Business

Table 24. Mirna Therapeutics RNAi for Therapeutic Product and Solutions

Table 25. Mirna Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Quark Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 27. Quark Pharmaceuticals Major Business

Table 28. Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions

Table 29. Quark Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. RXi Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 31. RXi Pharmaceuticals Major Business

Table 32. RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions

Table 33. RXi Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Silence Therapeutics Corporate Information, Head Office, and Major Competitors

Table 35. Silence Therapeutics Major Business

Table 36. Silence Therapeutics RNAi for Therapeutic Product and Solutions

Table 37. Silence Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Benitec Biopharma Corporate Information, Head Office, and Major Competitors

Table 39. Benitec Biopharma Major Business

Table 40. Benitec Biopharma RNAi for Therapeutic Product and Solutions

Table 41. Benitec Biopharma RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. miRagen Therapeutics Corporate Information, Head Office, and Major Competitors

Table 43. miRagen Therapeutics Major Business

Table 44. miRagen Therapeutics RNAi for Therapeutic Product and Solutions

Table 45. miRagen Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Sylentis Corporate Information, Head Office, and Major Competitors

Table 47. Sylentis Major Business

Table 48. Sylentis RNAi for Therapeutic Product and Solutions

Table 49. Sylentis RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Gradalis Corporate Information, Head Office, and Major Competitors

Table 51. Gradalis Major Business

Table 52. Gradalis RNAi for Therapeutic Product and Solutions

Table 53. Gradalis RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Sirnaomics Corporate Information, Head Office, and Major Competitors

Table 55. Sirnaomics Major Business

Table 56. Sirnaomics RNAi for Therapeutic Product and Solutions

Table 57. Sirnaomics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Silenseed Corporate Information, Head Office, and Major Competitors

Table 59. Silenseed Major Business

Table 60. Silenseed RNAi for Therapeutic Product and Solutions

Table 61. Silenseed RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Global RNAi for Therapeutic Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 63. Global RNAi for Therapeutic Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 64. Breakdown of RNAi for Therapeutic by Company Type (Tier 1, Tier 2 and Tier 3)

Table 65. RNAi for Therapeutic Players Head Office, Products and Services Provided

Table 66. RNAi for Therapeutic Mergers & Acquisitions in the Past Five Years

Table 67. RNAi for Therapeutic New Entrants and Expansion Plans

Table 68. Global RNAi for Therapeutic Revenue (USD Million) by Type (2017-2022)

Table 69. Global RNAi for Therapeutic Revenue Share by Type (2017-2022)

Table 70. Global RNAi for Therapeutic Revenue Forecast by Type (2023-2028)

Table 71. Global RNAi for Therapeutic Revenue by Application (2017-2022)

Table 72. Global RNAi for Therapeutic Revenue Forecast by Application (2023-2028)

Table 73. North America RNAi for Therapeutic Revenue by Type (2017-2022) & (USD Million)

Table 74. North America RNAi for Therapeutic Revenue by Type (2023-2028) & (USD Million)

Table 75. North America RNAi for Therapeutic Revenue by Application (2017-2022) & (USD Million)

Table 76. North America RNAi for Therapeutic Revenue by Application (2023-2028) & (USD Million)

Table 77. North America RNAi for Therapeutic Revenue by Country (2017-2022) & (USD Million)

Table 78. North America RNAi for Therapeutic Revenue by Country (2023-2028) & (USD Million)

Table 79. Europe RNAi for Therapeutic Revenue by Type (2017-2022) & (USD Million)

Table 80. Europe RNAi for Therapeutic Revenue by Type (2023-2028) & (USD Million)

Table 81. Europe RNAi for Therapeutic Revenue by Application (2017-2022) & (USD Million)

Table 82. Europe RNAi for Therapeutic Revenue by Application (2023-2028) & (USD Million)

Table 83. Europe RNAi for Therapeutic Revenue by Country (2017-2022) & (USD Million)

Table 84. Europe RNAi for Therapeutic Revenue by Country (2023-2028) & (USD Million)

Table 85. Asia-Pacific RNAi for Therapeutic Revenue by Type (2017-2022) & (USD Million)

Table 86. Asia-Pacific RNAi for Therapeutic Revenue by Type (2023-2028) & (USD Million)

Table 87. Asia-Pacific RNAi for Therapeutic Revenue by Application (2017-2022) & (USD Million)

Table 88. Asia-Pacific RNAi for Therapeutic Revenue by Application (2023-2028) & (USD Million)

Table 89. Asia-Pacific RNAi for Therapeutic Revenue by Region (2017-2022) & (USD Million)

Table 90. Asia-Pacific RNAi for Therapeutic Revenue by Region (2023-2028) & (USD Million)

Table 91. South America RNAi for Therapeutic Revenue by Type (2017-2022) & (USD Million)

Table 92. South America RNAi for Therapeutic Revenue by Type (2023-2028) & (USD Million)

Table 93. South America RNAi for Therapeutic Revenue by Application (2017-2022) & (USD Million)

Table 94. South America RNAi for Therapeutic Revenue by Application (2023-2028) & (USD Million)

Table 95. South America RNAi for Therapeutic Revenue by Country (2017-2022) & (USD Million)

Table 96. South America RNAi for Therapeutic Revenue by Country (2023-2028) & (USD Million)

Table 97. Middle East & Africa RNAi for Therapeutic Revenue by Type (2017-2022) & (USD Million)

Table 98. Middle East & Africa RNAi for Therapeutic Revenue by Type (2023-2028) & (USD Million)

Table 99. Middle East & Africa RNAi for Therapeutic Revenue by Application (2017-2022) & (USD Million)

Table 100. Middle East & Africa RNAi for Therapeutic Revenue by Application (2023-2028) & (USD Million)

Table 101. Middle East & Africa RNAi for Therapeutic Revenue by Country (2017-2022) & (USD Million)

Table 102. Middle East & Africa RNAi for Therapeutic Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. RNAi for Therapeutic Picture

Figure 2. Global RNAi for Therapeutic Revenue Market Share by Type in 2021

Figure 3. siRNA

Figure 4. miRNA

Figure 5. shRNA

Figure 6. RNAi for Therapeutic Revenue Market Share by Application in 2021

Figure 7. Cancer Picture

Figure 8. Cardiovascular Picture

Figure 9. HBV Picture

Figure 10. Others Picture

Figure 11. Global RNAi for Therapeutic Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 12. Global RNAi for Therapeutic Revenue and Forecast (2017-2028) & (USD Million)

Figure 13. Global RNAi for Therapeutic Revenue Market Share by Region (2017-2028)

Figure 14. Global RNAi for Therapeutic Revenue Market Share by Region in 2021

Figure 15. North America RNAi for Therapeutic Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. Europe RNAi for Therapeutic Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Asia-Pacific RNAi for Therapeutic Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. South America RNAi for Therapeutic Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Middle East and Africa RNAi for Therapeutic Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. RNAi for Therapeutic Market Drivers

Figure 21. RNAi for Therapeutic Market Restraints

Figure 22. RNAi for Therapeutic Market Trends

Figure 23. Alnylam Pharmaceuticals Recent Developments and Future Plans

Figure 24. Arbutus Biopharma (Tekmira) Recent Developments and Future Plans

Figure 25. Arrowhead Recent Developments and Future Plans

Figure 26. Dicerna Pharmaceuticals Recent Developments and Future Plans

Figure 27. Mirna Therapeutics Recent Developments and Future Plans

Figure 28. Quark Pharmaceuticals Recent Developments and Future Plans

Figure 29. RXi Pharmaceuticals Recent Developments and Future Plans

Figure 30. Silence Therapeutics Recent Developments and Future Plans

Figure 31. Benitec Biopharma Recent Developments and Future Plans

Figure 32. miRagen Therapeutics Recent Developments and Future Plans

Figure 33. Sylentis Recent Developments and Future Plans

Figure 34. Gradalis Recent Developments and Future Plans

Figure 35. Sirnaomics Recent Developments and Future Plans

Figure 36. Silenseed Recent Developments and Future Plans

Figure 37. Global RNAi for Therapeutic Revenue Share by Players in 2021

Figure 38. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 39. Global Top 3 Players RNAi for Therapeutic Revenue Market Share in 2021

Figure 40. Global Top 10 Players RNAi for Therapeutic Revenue Market Share in 2021

Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 42. Global RNAi for Therapeutic Revenue Share by Type in 2021

Figure 43. Global RNAi for Therapeutic Market Share Forecast by Type (2023-2028)

Figure 44. Global RNAi for Therapeutic Revenue Share by Application in 2021

Figure 45. Global RNAi for Therapeutic Market Share Forecast by Application (2023-2028)

Figure 46. North America RNAi for Therapeutic Sales Market Share by Type (2017-2028)

Figure 47. North America RNAi for Therapeutic Sales Market Share by Application (2017-2028)

Figure 48. North America RNAi for Therapeutic Revenue Market Share by Country (2017-2028)

Figure 49. United States RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. Canada RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. Mexico RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Europe RNAi for Therapeutic Sales Market Share by Type (2017-2028)

Figure 53. Europe RNAi for Therapeutic Sales Market Share by Application (2017-2028)

Figure 54. Europe RNAi for Therapeutic Revenue Market Share by Country (2017-2028)

Figure 55. Germany RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. France RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. United Kingdom RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Russia RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Italy RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Asia-Pacific RNAi for Therapeutic Sales Market Share by Type (2017-2028)

Figure 61. Asia-Pacific RNAi for Therapeutic Sales Market Share by Application (2017-2028)

Figure 62. Asia-Pacific RNAi for Therapeutic Revenue Market Share by Region (2017-2028)

Figure 63. China RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Japan RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. South Korea RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. India RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Southeast Asia RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Australia RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. South America RNAi for Therapeutic Sales Market Share by Type (2017-2028)

Figure 70. South America RNAi for Therapeutic Sales Market Share by Application (2017-2028)

Figure 71. South America RNAi for Therapeutic Revenue Market Share by Country (2017-2028)

Figure 72. Brazil RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. Argentina RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Middle East and Africa RNAi for Therapeutic Sales Market Share by Type (2017-2028)

Figure 75. Middle East and Africa RNAi for Therapeutic Sales Market Share by Application (2017-2028)

Figure 76. Middle East and Africa RNAi for Therapeutic Revenue Market Share by Country (2017-2028)

Figure 77. Turkey RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. Saudi Arabia RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 79. UAE RNAi for Therapeutic Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Methodology

Figure 81. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz